Skip to main content
SpringerLink
Log in
Book cover

Breast Cancer pp 303–310Cite as

In Situ Cancer Treatment

  • Chapter
  • First Online:

  • 2166 Accesses

Abstract

Lobular carcinoma in situ is a marker for an increased risk of breast cancer and a non-obligate precursor of invasive carcinoma. Morphological variants of pleomorphic LCIS are accepted as more complex lesions and are more likely to be associated with invasive carcinoma. Ductal carcinoma in situ (DCIS) is a heterogeneous group of diseases that differ in biology and clinical behavior. DCIS is the putative precursor of the majority of invasive breast cancers, and its incidence has increased dramatically with mammographic screening. The goal of the management of DCIS is to prevent the development of invasive breast cancer. This chapter focuses on recommendations for workup, primary treatment, risk reduction strategies, and surveillance specific to carcinoma in situ, which represents approximately 20% of all breast cancers diagnosed by mammography.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   99.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   179.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. O’Neil M, Madan R, Tawfik OW, Thomas PA, Fan F. Lobular carcinoma in situ/atypical lobular hyperplasia on breast needle biopsies: does it warrant surgical excisional biopsy? A study of 27 cases. Ann Diagn Pathol. 2010;14:251–5.

    Article  Google Scholar 

  2. College of American Pathologists. Protocols and guidelines. Available at: http://www.cap.org. Accessed 26 Feb 2018.

  3. EORTC Breast Cancer Cooperative Group, EORTC Radiotherapy Group, Bijker N, Meijnen P, Peterse JL, Bogaerts J, Van Hoorebeeck I, Julien JP, et al. Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in-situ: ten-year results of European Organisation for Research and Treatment of Cancer randomized phase III trial 10853--a study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. J Clin Oncol. 2006;24:3381–7.

    Article  Google Scholar 

  4. Gradishar WJ, Anderson BO, Balassanian R. Breast Cancer, version 4.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2018;16(3):310–20.

    Article  Google Scholar 

  5. Leidenius M, Salmenkivi K, von Smitten K, Heikkilä P. Tumour-positive sentinel node findings in patients with ductal carcinoma in situ. J Surg Oncol. 2006;94:380–4.

    Article  CAS  Google Scholar 

  6. Moore KH, Sweeney KJ, Wilson ME, Goldberg JI, Buchanan CL, Tan LK, et al. Outcomes for women with ductal carcinoma-in-situ and a positive sentinel node: a multi-institutional audit. Ann Surg Oncol. 2007;14:2911–7.

    Article  Google Scholar 

  7. Meijnen P, Oldenburg HS, Loo CE, Nieweg OE, Peterse JL, Rutgers EJ. Risk of invasion and axillary lymph node metastasis in ductal carcinoma in situ diagnosed by core-needle biopsy. Br J Surg. 2007;94:952–6.

    Article  CAS  Google Scholar 

  8. Yen TW, Hunt KK, Ross MI, Mirza NQ, Babiera GV, Meric-Bernstam F. Predictors of invasive breast cancer in patients with an initial diagnosis of ductal carcinoma in situ: a guide to selective use of sentinel lymph node biopsy in management of ductal carcinoma in situ. J Am Coll Surg. 2005;200:516–26.

    Article  Google Scholar 

  9. Cody HS 3rd, Van Zee KJ. Point: sentinel lymph node biopsy is indicated for patients with DCIS. J Natl Compr Cancer Netw. 2003;1:199–206.

    Article  Google Scholar 

  10. Silverstein MJ, Lagios MD, Groshen S, Waisman JR, Lewinsky BS, Martino S, et al. The influence of margin width on local control of ductal carcinoma in situ of the breast. N Engl J Med. 1999;340:1455–61.

    Article  CAS  Google Scholar 

  11. Morrow M, Van Zee KJ, Solin LJ, Houssami N, Chavez-MacGregor M, Harris JR, et al. Society of Surgical Oncology-American Society for Radiation Oncology-American Society of Clinical Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in ductal carcinoma in situ. J Clin Oncol. 2016;34:4040–6.

    Article  Google Scholar 

  12. Shah C, Vicini F, Shaitelman SF, Hepel J, Keisch M, Arthur D, et al. The American Brachytherapy Society consensus statement for accelerated partial-breast irradiation. Brachytherapy. 2018;17(1):154–70.

    Article  Google Scholar 

  13. ASBS: http://www.breastsurgeons.org/statements/apbi_statement_revised_100708.pdf.

  14. ABS: http://www.americanbrachytherapy.org/recources/abs_breast_brachytherapy_taskgroup.Pdf.

  15. Hughes LL, Wang M, Page DL, Gray R, Solin LJ, Davidson NE, et al. Local excision alone without irradiation for ductal carcinoma in situ of the breast: a trial of the eastern cooperative oncology group. J Clin Oncol. 2009;27:5319–24.

    Article  Google Scholar 

  16. McCormick B, Winter K, Hudis C, Kuerer HM, Rakovitch E, Smith BL, et al. RTOG 9804: a prospective randomized trial for good-risk ductal carcinoma in situ comparing radiotherapy with observation. J Clin Oncol. 2015;33(7):709–15.

    Article  CAS  Google Scholar 

  17. Smith B. When is good enough really good enough? Defining the role of radiation in low-risk ductal carcinoma in situ. J Clin Oncol. 2015;33(7):686–91.

    Article  Google Scholar 

  18. Lagios MD, Silverstein MJ. Ductal carcinoma in situ: recent history and areas of controversy. Breast J. 2015;21:21–6.

    Article  Google Scholar 

  19. Fisher B, Dignam J, Wolmark N, Mamounas E, Costantino J, Poller W, et al. Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: findings from the National Surgical Adjuvant Breast and Bowel Project B-17. J Clin Oncol. 1998;16:441–52.

    Article  CAS  Google Scholar 

  20. Julien JP, Bijker N, Fentiman IS, Peterse JL, Delledonne V, Rouanet P, et al. Radiotherapy in breast conserving treatment for ductal carcinoma in situ: first results of the EORCT randomized phase III trial 10853. Lancet. 2000;353:528–33.

    Article  Google Scholar 

  21. UK Coordinating Committee on Cancer Research. Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: randomized controlled trial. Lancet. 2003;362:95–102.

    Article  Google Scholar 

  22. Fisher B, Land S, Mamounas E, Dignam J, Fisher ER, Wolmark N. Prevention of invasive breast cancer in women with ductal carcinoma in situ: An update of the national surgical adjuvant breast and bowel project experience. Semin Oncol. 2001;28:400–18.

    Article  CAS  Google Scholar 

  23. Staley H, McCallum I, Bruce J. Postoperative Tamoxifen for ductal carcinoma in situ: Cochrane systematic review and meta-analysis. Breast. 2014;23:546–51.

    Article  CAS  Google Scholar 

  24. Forbes F, Sestak I, Howell A, Bonanni B, Bundred N, Levy C, et al. Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial. Lancet. 2016;387:866–73.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgical Oncology, Institute of Oncology, Istanbul University, Istanbul, Turkey

    Hasan Karanlik

  2. General Surgery, Istanbul Medical Faculty, Department of Surgery, Istanbul University, Istanbul, Turkey

    Abdullah Igci

Authors
  1. Hasan Karanlik
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Abdullah Igci
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Abdullah Igci .

Editor information

Editors and Affiliations

  1. Internal Medicine, Medical Oncology, Istanbul Medical Faculty, Department of Medical Oncology, Institute of Oncology, Istanbul University, Istanbul, Turkey

    Adnan Aydiner

  2. General Surgery, Istanbul Medical Faculty, Department of Surgery, Istanbul University, Istanbul, Turkey

    Abdullah Igci

  3. Surgical Oncology, Magee-Women’s Hospital, University of Pittsburgh Medical Centre, Pittsburgh, PA, USA

    Atilla Soran

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Karanlik, H., Igci, A. (2019). In Situ Cancer Treatment. In: Aydiner, A., Igci, A., Soran, A. (eds) Breast Cancer . Springer, Cham. https://doi.org/10.1007/978-3-319-96947-3_12

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-96947-3_12

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-96946-6

  • Online ISBN: 978-3-319-96947-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation